Zacks Investment Research
23 Jun 2026, 15:55 UTC · 1h ago
Definium Stock Soars 50% as Phase III Depression Study Meets Key Goals
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
23 Jun 2026, 15:55 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Definium Therapeutics' lead candidate DT120 met its primary and all key secondary efficacy endpoints in a Phase III study for major depressive disorder. — Positive late-stage clinical trial results for a lead asset are primary catalysts for biotech valuation and potential FDA approval.
+0.80DT120 demonstrated a clinically meaningful 8.1-point placebo-adjusted reduction in depressive symptoms (MADRS score) at week 6. — Quantifiable efficacy data provides the fundamental evidence needed for market confidence in the drug's viability.
+0.60The therapy is developed as a single-dose treatment producing rapid symptom relief, potentially disrupting the standard daily-administration antidepressant model. — A successful transition to single-dose therapy represents a significant competitive advantage and market expansion opportunity.
+0.50Which stocks this story touches
Continue reading
6 related stories
Search tags
Shares surged nearly 50% following positive top-line results from a late-stage study for its lead pipeline candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
4h ago
